Calidi Biotherapeutics Stock Market Outlook
| CLDI Stock | 0.78 0.02 2.63% |
Under 67% of Calidi Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Calidi Biotherapeutics suggests that many traders are alarmed. Calidi Biotherapeutics' investing sentiment shows overall attitude of investors towards Calidi Biotherapeutics.
Comfort Level 33
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Calidi Biotherapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Calidi Biotherapeutics.
News SentimentBearish | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Calidi Biotherapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Calidi Biotherapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Execute Calidi Biotherapeutics Advice
The Calidi recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Calidi Biotherapeutics. Macroaxis does not own or have any residual interests in Calidi Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Calidi Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Calidi Biotherapeutics has a Mean Deviation of 2.61, Standard Deviation of 3.49 and Variance of 12.16We provide trade advice to complement the prevailing expert consensus on Calidi Biotherapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Calidi Biotherapeutics is not overpriced, please confirm all Calidi Biotherapeutics fundamentals, including its cash flow from operations, market capitalization, and the relationship between the net income and target price . As Calidi Biotherapeutics appears to be a penny stock we also recommend to validate its price to book numbers.
Calidi Biotherapeutics Trading Alerts and Improvement Suggestions
| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Calidi Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| About 23.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - The News-Star |
Calidi Biotherapeutics Returns Distribution Density
The distribution of Calidi Biotherapeutics' historical returns is an attempt to chart the uncertainty of Calidi Biotherapeutics' future price movements. The chart of the probability distribution of Calidi Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use Calidi Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Calidi Biotherapeutics returns is essential to provide solid investment analysis for Calidi Biotherapeutics.
| Mean Return | -0.81 | Value At Risk | -7.14 | Potential Upside | 4.48 | Standard Deviation | 3.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Calidi Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Calidi Biotherapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (215K) | (360K) | (478K) | (16K) | (18.4K) | (19.3K) | |
| Change In Cash | 1.8M | (590.7K) | 1.6M | 7.6M | 8.8M | 9.2M | |
| Net Borrowings | 1.8M | 1.4M | 899K | 1.9M | 1.7M | 1.3M | |
| Free Cash Flow | (8.0M) | (13.6M) | (27.6M) | (19.7M) | (17.7M) | (18.6M) | |
| Depreciation | 153K | 260K | 1.3M | 1.5M | 1.8M | 1.9M | |
| Other Non Cash Items | 582K | 8.4M | 2.4M | (279K) | (251.1K) | (238.5K) | |
| Capital Expenditures | 206K | 428K | 585K | 16K | 14.4K | 13.7K | |
| Net Income | (10.9M) | (25.4M) | (29.2M) | (22.2M) | (20.0M) | (21.0M) | |
| End Period Cash Flow | 2.2M | 472K | 2.2M | 9.8M | 11.3M | 11.8M |
Calidi Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Calidi Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Calidi Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Calidi stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.91 | |
β | Beta against Dow Jones | 1.42 | |
σ | Overall volatility | 3.47 | |
Ir | Information ratio | -0.25 |
Calidi Biotherapeutics Volatility Alert
Calidi Biotherapeutics exhibits very low volatility with skewness of -0.59 and kurtosis of 1.11. Calidi Biotherapeutics is a potential penny stock. Although Calidi Biotherapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Calidi Biotherapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Calidi instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Calidi Biotherapeutics Fundamentals Vs Peers
Comparing Calidi Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Calidi Biotherapeutics' direct or indirect competition across all of the common fundamentals between Calidi Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Calidi Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Calidi Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Calidi Biotherapeutics to competition |
| Fundamentals | Calidi Biotherapeutics | Peer Average |
| Return On Asset | -1.2 | -0.14 |
| Current Valuation | (1.46 M) | 16.62 B |
| Shares Outstanding | 7.17 M | 571.82 M |
| Shares Owned By Insiders | 23.20 % | 10.09 % |
| Shares Owned By Institutions | 5.30 % | 39.21 % |
| Number Of Shares Shorted | 259.45 K | 4.71 M |
| Price To Book | 0.81 X | 9.51 X |
| Price To Sales | 50.83 X | 11.42 X |
| Gross Profit | 31 K | 27.38 B |
| EBITDA | (19.73 M) | 3.9 B |
| Net Income | (22.21 M) | 570.98 M |
| Total Debt | 7.04 M | 5.32 B |
| Book Value Per Share | 0.98 X | 1.93 K |
| Cash Flow From Operations | (19.69 M) | 971.22 M |
| Short Ratio | 3.24 X | 4.00 X |
| Earnings Per Share | 0.36 X | 3.12 X |
| Target Price | 120.0 | |
| Number Of Employees | 28 | 18.84 K |
| Beta | 1.09 | -0.15 |
| Market Capitalization | 5.61 M | 19.03 B |
| Total Asset | 14.18 M | 29.47 B |
| Retained Earnings | (121.72 M) | 9.33 B |
| Working Capital | 731 K | 1.48 B |
| Net Asset | 14.18 M |
Note: Disposition of 850 shares by Allan Camaisa of Calidi Biotherapeutics at 1.455 subject to Rule 16b-3 [view details]
Calidi Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Calidi . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Calidi Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell Calidi Biotherapeutics? Buying financial instruments such as Calidi Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Calidi Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Services Thematic Idea Now
Communication Services
Companies that provide networking, telecom, and long distance services. The Communication Services theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Calidi Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.